BeiGene Ltd Ordinary Shares (SEHK:6160)
APAC company
Share Price Chart
- Chart currently unavailable -
Market Info - 6160
- Market Open Price0.00
- Previous Close0.00
- Volume-
- 52w Low/High-
- Last Trade Price0.00
- Bid/Ask Price0.00
Company Info - 6160
- Market CapHKD0.000m
- SymbolSEHK:6160
- IndustryHealthcare
- SectorBiotechnology
- Currency
- ISINKYG1146Y1017
Company Profile
BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent.
Latest 6160 news
Currently there for this company. Visit our news hub for other news .